{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:40:01Z","timestamp":1765892401298,"version":"3.48.0"},"reference-count":24,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["21mk0101159h0003"],"award-info":[{"award-number":["21mk0101159h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,10,7]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine the incidence of stroke or systemic embolic events (SSEs) and bleeding events in untreated patients with non-valvular atrial fibrillation (NVAF) after widespread use of direct oral anticoagulant agents (DOACs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Multicentre, non-interventional, observational, retrospective cohort study using real-world data in Japan (2016-2018).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The Mie, Musashino University study of NVAF, which used the Mie-Life Innovation Promotion Center Database. This is a regional clinical database involving one university hospital and eight general hospitals in Mie Prefecture in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Japanese patients with NVAF (n=7001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome<\/jats:title>\n                    <jats:p>The incidence of SSEs and bleeding events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 7001 patients with NAVF were registered, and 53.0% were treated with DOACs, 10.6% were treated with warfarin and 36.4% had no treatment. Additionally, 29.5% of patients with a CHADS2 (congestive heart failure, hypertension, age\u226575 years, diabetes, previous stroke or transient ischemic attack) score of 3\u20136 were untreated. In the no treatment group, the SSE rates by the CHADS2 score (0, 1, 2 and 3\u20136) were 1.4%, 1.4%, 3.2% and 8.0%, respectively. The rates of bleeding events by the CHADS2 score (0, 1, 2 and 3\u20136) in the no treatment group were 0.7%, 1.0%, 1.2% and 2.9%, respectively. A multivariate analysis of SSEs in components of the CHADS2 showed that the adjusted HRs were 2.32 for heart failure, 1.66 for an age \u226575 years, 1.81 for diabetes mellitus and 5.84 for prior stroke or transient ischaemic attack.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately one-third of the patients do not receive any anticoagulation in the modern DOAC era in Japan. The SSE rate increases by the CHADS2 score. The SSE rate is low in patients with a CHADS2 score &lt;1, supporting no indication of anticoagulation in current guidelines. In patients with a CHADS2 score &gt;1, the use of anticoagulant drug therapy is recommended because of a higher risk of stroke.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063623","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T10:01:39Z","timestamp":1668074499000},"page":"e063623","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of stroke, systemic embolism and bleeding events in patients without anticoagulation based on real-world data in Japan: a retrospective cohort study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-7018","authenticated-orcid":false,"given":"Kimihiko","family":"Tanizawa","sequence":"first","affiliation":[{"name":"Clinical Development Department III, Daiichi Sankyo Co Ltd., Shinagawa R and D Center, Shinagawa, Tokyo, Japan"},{"name":"Laboratory of Regulatory Science, Research Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, Mie University Hospital, Tsu, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Sera","sequence":"additional","affiliation":[{"name":"Laboratory of Regulatory Science, Research Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Yaguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Regulatory Science, Research Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[{"name":"Laboratory of Regulatory Science, Research Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, Mie University Hospital, Tsu, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, Mie University Hospital, Tsu, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Nagai","sequence":"additional","affiliation":[{"name":"Laboratory of Regulatory Science, Research Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2025121605355104000_12.11.e063623.1","unstructured":"Change in the population pyramid. Available: http:\/\/www.mhlw.go.jp\/english\/social_security\/kaikaku_1.html [Accessed 01 Nov 2022]."},{"key":"2025121605355104000_12.11.e063623.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2008.06.029"},{"key":"2025121605355104000_12.11.e063623.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864"},{"key":"2025121605355104000_12.11.e063623.4","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"2025121605355104000_12.11.e063623.5","first-page":"e199","article-title":"AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","volume":"2014","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2025121605355104000_12.11.e063623.6","unstructured":". Available: http:\/\/www.pmda.go.jp\/drugs\/2011\/P201100019\/530353000_22300AMX00433000_A100_1.pdf [Accessed 01 Nov 2022]."},{"key":"2025121605355104000_12.11.e063623.7","unstructured":". Available: http:\/\/www.pmda.go.jp\/drugs\/2012\/P201200011\/630004000_22400AMX00041_A100_2.pdf [Accessed 01 Nov 2022]."},{"key":"2025121605355104000_12.11.e063623.8","unstructured":". Available: http:\/\/www.pmda.go.jp\/drugs\/2012\/P201200166\/670605000_22400AMX01496_A100_1.pdf [Accessed 01 Nov 2022]."},{"key":"2025121605355104000_12.11.e063623.9","unstructured":". Available: http:\/\/www.pmda.go.jp\/drugs\/2014\/P201400133\/430574000_22300AMX00547_A100_1.pdf [Accessed 01 Nov 2022]."},{"key":"2025121605355104000_12.11.e063623.10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3820\/jjpe.22.37","article-title":"Application of the Real World Data for Pharmacoepidemiology Reserach &gt","volume":"22","author":"Kawakami","year":"2017","journal-title":"Japanese Journal of Pharmacoepidemiology\/Yakuzai ekigaku"},{"key":"2025121605355104000_12.11.e063623.11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2016.10.015","article-title":"Usefulness of a healthcare database for epidemiological research in atrial fibrillation","volume":"70","author":"Koretsune","year":"2017","journal-title":"J Cardiol"},{"key":"2025121605355104000_12.11.e063623.12","first-page":"87","article-title":"The epidemiological study of venous thromboembolism and bleeding events using a Japanese healthcare database -validation study","volume":"17","author":"Yamaguchi","year":"2015","journal-title":"Jpn J Drug Inform"},{"key":"2025121605355104000_12.11.e063623.13","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"2025121605355104000_12.11.e063623.14","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-10-1119"},{"key":"2025121605355104000_12.11.e063623.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2011.06.006"},{"key":"2025121605355104000_12.11.e063623.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2012.12.002"},{"key":"2025121605355104000_12.11.e063623.17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1253\/circj.CJ-18-0991","article-title":"Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF registry","volume":"83","author":"Murata","year":"2019","journal-title":"Circ J"},{"key":"2025121605355104000_12.11.e063623.18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"2025121605355104000_12.11.e063623.19","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-1131"},{"key":"2025121605355104000_12.11.e063623.20","unstructured":"JCS\/JHRS . Guideline on pharmacotherapy of cardiac arrhythmias, 2020. Available: https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2020\/01\/JCS2020_Ono.pdf [Accessed 01 Nov 2022]."},{"key":"2025121605355104000_12.11.e063623.21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"ELDERCARE-AF committees and Investigators. low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"2025121605355104000_12.11.e063623.22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1253\/circj.CJ-16-1267","article-title":"Risk of Ischemic Stroke in Patients With Non-Valvular Atrial Fibrillation Not Receiving Oral Anticoagulants\u3000- Korean Nationwide Population-Based Study","volume":"81","author":"Kang","year":"2017","journal-title":"Circ J"},{"key":"2025121605355104000_12.11.e063623.23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/17474930211046743","article-title":"Oral anticoagulation improves survival in very elderly Chinese patients with atrial fibrillation: a report from the optimal thromboprophylaxis in elderly Chinese patients with atrial fibrillation (ChiOTEAF) registry","volume":"17","author":"Guo","year":"2022","journal-title":"Int J Stroke"},{"key":"2025121605355104000_12.11.e063623.24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1253\/circj.CJ-20-1075","article-title":"A novel risk stratification system for ischemic stroke in Japanese patients with non-valvular atrial fibrillation","volume":"85","author":"Okumura","year":"2021","journal-title":"Circ J"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:36:00Z","timestamp":1765892160000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,10]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/bmjopen-2022-063623"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063623","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}